Upcoming events

Upcoming events

myNEO Therapeutics will attend job fairs and participate in the following events: Esmo Immuno-Oncology 2024 – Genève, Switzerland – December 11 – December 13, 2024 Benelux Drug Development Symposium 2.0 – Utrecht, Netherlands – November 28,2024 Bio...

OUR LATEST POST

CAMYO-01 Update

Our CEO, Cedric Bogaert, shares exciting news: "I'm glad to share the latest results of our CAMYO-01 program (shared colorectal cancer vaccine) with LinkedIn as well. We've presented these results in the past month on several scientific conferences, and appreciated...

ALL POSTS

All

News

Press release

Article

Dec 4 2024

CAMYO-01 Update

Our CEO, Cedric Bogaert, shares exciting news: “I’m glad to share the latest results of our CAMYO-01 program (shared colorectal cancer vac...

Dec 4 2024

Antigen Target Library

🚀 Advancing Immunotherapy through Antigen Target Screening We’re excited to announce the creation of an innovative antigen target library, built from ...

Sep 16 2024

CAMYO-02 Update

Our CEO, Cedric Bogaert, shares exciting news:“Happy to provide insight into a secondary program we’ve applied our focus and technology to. Panc...

Sep 5 2024

Presentation Ontmoeting Ontspanning Kanker vzw

🌟 We are excited to announce that Lien will be speaking at an event organized by Ontmoeting en Ontspanning Kanker titled “Personalized Immunothe...

Sep 3 2024

Upcoming events

myNEO Therapeutics will attend job fairs and participate in the following events:

May 30 2024

SOB Case Study

Following antigen discovery and validation, mRNA construct design can be challenging. Read this case study to learn more about how to design multi-epi...

Dec 4 2024

CAMYO-01 Update

Our CEO, Cedric Bogaert, shares exciting news: “I’m glad to share the latest results of our CAMYO-01 program (shared colorectal cancer vac...

Dec 4 2024

Antigen Target Library

🚀 Advancing Immunotherapy through Antigen Target Screening We’re excited to announce the creation of an innovative antigen target library, built from ...

Sep 16 2024

CAMYO-02 Update

Our CEO, Cedric Bogaert, shares exciting news:“Happy to provide insight into a secondary program we’ve applied our focus and technology to. Panc...

Sep 5 2024

Presentation Ontmoeting Ontspanning Kanker vzw

🌟 We are excited to announce that Lien will be speaking at an event organized by Ontmoeting en Ontspanning Kanker titled “Personalized Immunothe...

Sep 3 2024

Upcoming events

myNEO Therapeutics will attend job fairs and participate in the following events:

May 30 2024

SOB Case Study

Following antigen discovery and validation, mRNA construct design can be challenging. Read this case study to learn more about how to design multi-epi...

Nov 22 2023

CureVac exercises options in strategic collaboration with myNEO Therapeutics.

GHENT, Belgium and Tübingen, Germany/Boston, USA – November 22, 2023 – myNEO N.V. (myNEO Therapeutics) and CureVac N.V. (Nasdaq CVAC) announced today ...

Oct 25 2023

myNEO evolves into myNEO Therapeutics

myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics. myNEO, a biotech company...

Feb 13 2023

Odimma partners with myNEO Therapeutics for the clinical development of its personalized DNA-based cancer immunotherapy

Odimma Therapeutics and myNEO Therapeutics will partner to identify personalized targets for clinical development of DNA-based cancer vaccine therapy....

May 25 2022

CureVac Partners with myNEO Therapeutics to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

CureVac (Nasdaq: CVAC) and myNEO Therapeutics will partner to identify novel targets for mRNA-based cancer vaccine development. We’re convinced that c...

Apr 7 2021

OncoDNA and myNEO Therapeutics Join Forces to Unlock the Power of Personalized Vaccines

Fighting Cancer with Personalized Vaccines: ONCODNA and myNEO Therapeutics collaboration OncoDNA, a company specializing in precision medicine, and my...

May 30 2024

SOB Case Study

Following antigen discovery and validation, mRNA construct design can be challenging. Read this case study to learn more about how to design multi-epi...

Nov 16 2023

myNEO Therapeutic’s CEO Cedric Bogaert receives Medical Genetics award at the Vatican!

myNEO Therapeutics has been quite active in recent months, taking part in various conference presentations and participating in panel discussions abou...

Oct 17 2023

Hookipa-HPV Case Study

Are AI-driven insights the future of precision medicine, reshaping clinical data analysis as we know it? The inherent complexity of cancer a...

Aug 1 2023

Bloovi interview

At myNEO Therapeutics we are devoted to finding new and better targets for immunotherapy. With our validated antigen discovery technology, our amazing...

Nov 23 2022

Review publication in Cancer Cell

myNEO Therapeutics is extremely excited to announce the publication in the Cancer Cell journal, written by myNEO Therapeutics colleagues Lien, Steve, ...

Nov 14 2022

myNEO Therapeutics has won the 2022 Most Disruptive Innovator award

myNEO Therapeutics has won Deloitte’s 2022 Most Disruptive Innovator award. This award, which is part of the Rising Star category of the Deloitt...

Innovating immunotherapies,
transforming tomorrow

Subscribe to our newsletter

Get the latest news & updates about myNEO Therapeutics

Home

About us

Products

Technology

Partners

Services

Contact

Quick links

Publications

Latest news

Privacy statement

Terms of use

Careers

Cookie statement

We use cookies to enhance your browsing experience and provide analytics. By continuing to use this website, you agree to our use of cookies. For more information, please read our privacy statement.

myNEO BV

Ottergemsesteenweg-Zuid 808 B511, 9000 Ghent, East-Flanders
Belgium (BE0715710837)

Design by